{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-foot/prescribing-information/oral-itraconazole/","result":{"pageContext":{"chapter":{"id":"e3c1f25f-1a76-53af-aef4-b39eecdf04d7","slug":"oral-itraconazole","fullItemName":"Oral itraconazole","depth":2,"htmlHeader":"<!-- begin field c01f9124-755a-4570-a4dd-a8d200c4d10b --><h2>Oral itraconazole</h2><!-- end field c01f9124-755a-4570-a4dd-a8d200c4d10b -->","summary":"","htmlStringContent":"<!-- begin item 58f9badd-16c0-4407-80cc-a8d200c4ce88 --><!-- end item 58f9badd-16c0-4407-80cc-a8d200c4ce88 -->","topic":{"id":"32650c82-f347-5933-adc6-d0da00f3d764","topicId":"35b0fa0c-8988-453f-af54-60cd595d29ad","topicName":"Fungal skin infection - foot","slug":"fungal-skin-infection-foot","lastRevised":"Last revised in April 2018","chapters":[{"id":"66fe4516-176d-5ffc-aebd-99a58afbd57c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5231c18b-820c-586e-87f0-5527574f70d1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e2b3169b-582d-5dda-b94f-73ccd139eede","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8e1fd155-8f48-5bf7-a40c-4d2931a41736","slug":"changes","fullItemName":"Changes"},{"id":"8249fd1f-7c27-535b-a721-9e280d761ea5","slug":"update","fullItemName":"Update"}]},{"id":"e4ea5f16-99ef-5247-87e9-141b06d8b21a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"524d92eb-2792-5543-a6d9-78e4f825cf22","slug":"goals","fullItemName":"Goals"},{"id":"a678e6e3-5a4b-55cb-b7d6-c6ab9580eda2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"44708a93-b41d-5827-9293-650b191df0b0","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5d578224-3b80-58f6-9894-5c90e41c1b44","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a029f7b6-3344-51e6-ab22-bafdf196a4b7","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b487a461-1526-54bb-a2df-4e2e0562293d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0e034d35-5e8d-5db3-a518-77103caa73c8","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"73e18fb0-6f03-51ed-bddf-355959375e75","slug":"definition","fullItemName":"Definition"},{"id":"a33dea25-362f-5128-9c14-d178ef837bfe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"a4167228-e44b-560b-8406-20294a5b8e42","slug":"prevalence","fullItemName":"Prevalence"},{"id":"91f3fb6f-6926-547c-830c-dd963749fb55","slug":"complications","fullItemName":"Complications"},{"id":"8373f46b-763e-53e3-9ea8-90cd767d66e6","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"090da929-a640-586e-a803-a47b38656e1d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"024c307f-3650-539d-b0b4-4f1c4a8db49e","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e3544fc8-cba9-524d-aed2-f28ae6f802e8","slug":"assessment","fullItemName":"Assessment"},{"id":"3ad14837-2b4c-58ab-b5c5-456d63d403ae","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"db051fa9-f61e-5787-bd5d-b2ff4a77ba85","fullItemName":"Management","slug":"management","subChapters":[{"id":"a11a4a32-6cc1-5c40-8396-099a218e1487","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"27a2a883-b20f-5b25-825b-3bc5b02c1f77","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"476702d7-9e1a-5dfd-b3b0-899ebce5130b","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"e3c1f25f-1a76-53af-aef4-b39eecdf04d7","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"4f73cab3-f311-54bd-beac-8bb860f26e2f","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"aaec6565-5327-5bd4-bc06-a1442065c1bd","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c64c0494-1e71-5960-a8c9-a05141d2801c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"265ba112-5e5e-59c8-8569-29d1a263263d","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e7088451-abf0-5e2f-a546-109de8062cbf","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"96559e5f-dca9-5c90-af8c-c1182e5d3306","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"bd075cd9-9444-5680-bd23-a168ebe2b5a2","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"49b473c6-a745-5480-9602-1224549611f7","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"65b0f432-1967-593c-a9f7-2326776f4e83","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d96bb08c-b21d-517b-830e-ead35a26fe8e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9cd6e959-b2f0-51a3-9a11-fd1190ebde95","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 9aecf691-0ae4-4481-aed2-a8d200dc73eb --><h3>Dosing schedule</h3><!-- end field 9aecf691-0ae4-4481-aed2-a8d200dc73eb -->","summary":"","htmlStringContent":"<!-- begin item 6cf6716b-adf3-4e7d-a7e2-a8d200dc715f --><!-- begin field 04154f59-e994-4b13-92f1-a8d200dc73eb --><ul><li>For adults, prescribe itraconazole 100 mg once daily for 30 days, alternatively 200 mg twice daily for 7 days.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 04154f59-e994-4b13-92f1-a8d200dc73eb --><!-- end item 6cf6716b-adf3-4e7d-a7e2-a8d200dc715f -->","subChapters":[]},{"id":"480d322b-33e0-5572-b99c-efcfd12b063a","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 717c884b-9f1e-44cc-91be-a8d200c4f1ff --><h3>Contraindications and cautions</h3><!-- end field 717c884b-9f1e-44cc-91be-a8d200c4f1ff -->","summary":"","htmlStringContent":"<!-- begin item 7861f9bd-984b-477f-a564-a8d200c4efef --><!-- begin field 2a383052-b02b-42bd-82d2-a8d200c4f1ff --><p><strong>Do not prescribe itraconazole to people with:</strong></p><ul><li>Acute porphyria.</li><li>Ventricular dysfunction or a history of heart failure — itraconazole has been shown to have a negative inotropic effect.</li></ul><p><strong>Prescribe itraconazole with caution in people:</strong></p><ul><li>At high risk of heart failure, including people on treatment with negative inotropic drugs (such as calcium-channel blockers).</li><li>Who are immunocompromised (for example people with AIDS, on chemotherapy, have neutropenia, or previous organ transplants).</li><li>With acute liver disease, or a history of hepatotoxicity with other drugs — consider monitoring liver function tests (LFTs). Advise immediate LFTs if symptoms of possible liver toxicity develop, such as anorexia, nausea, vomiting, fatigue, abdominal pain, or dark urine.</li><li>With renal impairment.</li><li>Taking drugs such as astemizole, pimozide, quinidine, or terfenadine that may prolong the QT interval, as there is a risk of cardiac arrhythmias.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 2a383052-b02b-42bd-82d2-a8d200c4f1ff --><!-- end item 7861f9bd-984b-477f-a564-a8d200c4efef -->","subChapters":[]},{"id":"191bec45-e50b-5b08-871f-8b989057f2fa","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 4b4f6a6d-58d5-4ee4-9c86-a8d200c51332 --><h3>Adverse effects</h3><!-- end field 4b4f6a6d-58d5-4ee4-9c86-a8d200c51332 -->","summary":"","htmlStringContent":"<!-- begin item 8f4cdf58-3829-4516-bc29-a8d200c511bb --><!-- begin field 4c47eee0-e611-4d57-a5b0-a8d200c51332 --><p><strong>Adverse effects of itraconazole include:</strong></p><ul><li>Gastrointestinal — nausea, abdominal pain (common); vomiting, diarrhoea, constipation, dyspepsia, taste disturbance, flatulence (uncommon). Rarely pancreatitis.</li><li>Hepatobiliary — hyperbilirubinaemia (uncommon). Rarely hepatotoxicity (including acute liver failure).</li><li>Nervous system — headache, dizziness, paraesthesia (uncommon).</li><li>Skin and subcutaneous tissue — rash (common); alopecia, urticaria, pruritus (uncommon).</li><li>Other — arthralgia, myalgia, heart failure, erectile dysfunction, menstrual disorders, oedema, tinnitus, visual disturbance.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field 4c47eee0-e611-4d57-a5b0-a8d200c51332 --><!-- end item 8f4cdf58-3829-4516-bc29-a8d200c511bb -->","subChapters":[]},{"id":"7de13aa3-a528-560f-8b6e-718edba89c18","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3c355988-9e25-437a-baa9-a8d200c53201 --><h3>Drug interactions</h3><!-- end field 3c355988-9e25-437a-baa9-a8d200c53201 -->","summary":"","htmlStringContent":"<!-- begin item 55bf1f86-f409-446a-94ee-a8d200c53072 --><!-- begin field c00b934e-5815-4ae2-8cbb-a8d200c53201 --><p><strong>Itraconazole is metabolized by the cytochrome p450 3A4 (isoenzyme CYP34A) and it interacts with a number of liver enzyme-inducing and liver enzyme-inhibiting drugs.</strong></p><ul><li>Itraconazole levels may be reduced by the following drugs:<ul><li>Carbamazepine, phenobarbital, phenytoin — monitor itraconazole efficacy and increase dose if necessary.</li><li>Rifampicin, rifabutin — monitor itraconazole efficacy and increase dose if necessary.</li><li>St John’s wort — avoid concurrent use.</li></ul></li><li>Itraconazole levels may be increased by the following drugs:<ul><li>HIV protease inhibitors (ritonavir, indinavir) — monitor for adverse effects.</li><li>Clarithromycin and erythromycin — monitor for adverse effects.</li></ul></li><li>Itraconazole may increase levels of the following drugs:<ul><li>Aliskiren — monitor for adverse effects.</li><li>Aripiprazole, quetiapine, risperidone — dose reductions may be necessary.</li><li>Quetiapine — concurrent use with itraconazole is contraindicated. If considered necessary, monitor for adverse effects and adjust dose.</li><li>Phospodiesterase-5 inhibitors (avanafil, sildenafil, vardenafil) — avoid concurrent use with avanafil; reduce dose of sildenafil or vardenafil.</li><li>Benzodiazepines (alprazolam, triazolam, midazolam) — dose reductions may be required.</li><li>Calcium-channel blockers (amlodipine, verapamil) — monitor for adverse effects.</li><li>Colchicine — dose adjustment may be necessary.</li><li>Corticosteroids (budesonide, dexamethasone) — avoid concurrent use.</li><li>Digoxin — monitor the effects of digoxin; digoxin dose may need to be reduced by 50–75%.</li><li>Disopyramide — avoid concurrent use.</li><li>Domperidone — possible increased risk of ventricular arrhythmias. Avoid concurrent use.</li><li>Eplerenone — concurrent use is contraindicated.</li><li>Ergot alkaloids (such as ergotamine and ergometrine) — increased risk of ergotism. Concurrent use is contraindicated.</li><li>Ivabradine — concurrent use is contraindicated.</li><li>Mizolastine — monitor for adverse effects.</li><li>Oral anticoagulants (warfarin, apixaban, dabigatran). — Monitor for adverse effects and adjust doses if required.</li><li>Pimozide — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Quinidine — increased risk of torsades de pointes. Concurrent use is contraindicated, but if considered necessary, monitor for adverse effects and reduce dose if required.</li><li>Ranolazine — increased risk of QT interval prolongation. Concurrent use is contraindicated.</li><li>Reboxetine — monitor for adverse effects and adjust dose if required.</li><li>Solifenacin — restrict dose of solifenacin to 5 mg daily.</li><li>Statins (lovastatin, simvastatin) — avoid concurrent use.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">ABPI, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-foot/references/\">BNF 75, 2018</a>] </p><!-- end field c00b934e-5815-4ae2-8cbb-a8d200c53201 --><!-- end item 55bf1f86-f409-446a-94ee-a8d200c53072 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}